Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors Peter J. O'Dwyer, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Ursina R. Teitelbaum, Kathleen Harlacker, Lon S. Smith, Davendra Sohal, Drew Warren Rasco, Muralidhar Beeram, Mariam Mehran, Manal Tawashi, Michel A. Drouin, James Wang, Marielle Fournel, Chr
Title MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with erlotinib in patients with advanced solid tumors.
Journal J Clin Oncol
Abstract Text J Clin Oncol 30, 2012 (suppl; abstr e13602)


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown gastroesophageal junction adenocarcinoma not applicable Erlotinib + Glesatinib Phase I Actionable In a Phase I trial, 38% (3/8) of patients with gastroesophageal cancer remained on study for approximately 12-26 cycles with Glesatinib (MGCD265) and Tarceva (erlotinib) combination therapy (J Clin Oncol 30, 2012 (suppl; abstr e13602)). detail...
Unknown unknown Advanced Solid Tumor not applicable Erlotinib + Glesatinib Phase I Actionable In a Phase I trial, Glesatinib (MGCD265) and Tarceva (erlotinib) combination therapy demonstrated safety and preliminary clinical efficacy, resulted in partial response in 1 patient, and stable disease for 6 cycles or more in 16% (7/45) of patients with advanced solid tumors (J Clin Oncol 30, 2012 (suppl; abstr e13602)). detail...